



Newsletter from Emotra AB (publ)  
Göteborg, February 5, 2019

## Emotra: Marketing and research update

**Emotra AB (“Emotra”) is proud to announce that researchers have demonstrated a further application area for Emotra’s method EDOR®. Researchers at a psychiatric clinic have made a discovery that shows a possible further application of EDOR Test in clinical practice. Their results correlate with recent findings on the biological mechanism behind hyporeactivity.**

Research is a strategically important issue for Emotra, and we encourage and support clinics and research institutes that are interested in working with our technology in order to deepen this knowledge and disseminate it. A number of studies have now been completed or reached the point where they indicate new possible application areas for EDOR. This shows a potential for broader use of the test, considering hyporeactivity’s probable connection to various clinical challenges in patients diagnosed with depressions.

The Company is now investigating the conditions for patent protection of this broader application. Any patent application would need to be filed before we can reveal this new application, which means that we are unable to divulge any more information at this time. The authoring of a scientific paper is nearing completion, but the author is awaiting our patent application before submitting the paper for publication.

An article that describes the biological mechanism behind the phenomenon hyporeactivity is being written. This work is being led by Emotra’s Chief of Research and the inventor of EDOR, Lars-Håkan Thorell.

A manuscript for our clinical multi-center study, EUDOR-A, is ready. It has been sent to the participating researchers, who are in turn submitting their comments to the publication committee responsible for compiling the paper. We have not yet set a date for when we will submit this paper for publication.

In January, Emotra and a university hospital signed a letter of intent concerning the use of EDOR Test in the hospital’s clinical practice as well as to conduct a clinical study of their own.

**For further information, please contact:**

Daniel Poté, CEO, Telephone: +46 73 234 41 93, E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

---

*Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary, objective psychophysiological test for detecting hyporeactivity in patients suffering from depression.*

Emotra AB (publ), Göteborgsvägen 88, SE-433 63 Sävedalen, Sweden  
Tel: +46 73 234 41 93, [www.emotra.se](http://www.emotra.se)